Evidence map›Paper›PMID 42600024›Full record

ArticleScience advances2026

Ingestible probes for breath-based monitoring of drug-metabolizing activity from the microbiome.

Vishal A Manickam, Carly E Kimpling, Khoi N Le, Madeleine E Troussé, Amy Kang, Aarsh S Patel, Leslie W Chan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vishal A ManickamWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0000-0002-5625-868X
Carly E KimplingWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
Khoi N LeWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
Madeleine E TrousséWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0009-0008-9448-5761
Amy KangWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
Aarsh S PatelWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
Leslie W ChanWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0000-0002-0999-6890

Funding

T32 CTEng (Cellular and Tissue Engineering) Training ProgramT32GM145735 · NIGMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI Edward A. Botchwey, Andres J Garcia · 2022 to 2026
$2.3M
Engineering ingestible nanosensors for breath-based detection of colorectal cancerR37CA289714 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI LESLIE CHAN · 2025 to 2026
$1.2M
Engineering a diagnostic platform for rapid breath-based respiratory pathogen identification and treatment monitoringR00EB028311 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI CHAN, LESLIE · 2021 to 2023
$747k
NCI NIH HHS R37 CA289714NIBIB NIH HHS R00 EB028311NIGMS NIH HHS T32 GM145735
6 · The paper itself

Abstract

Due to their effects on drug activity and safety, drug-metabolizing enzymes (DMEs) from the gut microbiome are attractive drug targets, and noninvasive strategies are needed to measure their activities. Here, we report the development of ingestible probes that sense and produce breath signals for β-glucuronidase (GUS), a microbiome DME that causes drug toxicity. GUS probes comprise safe-to-ingest components and release volatile reporters upon cleavage by GUS. After oral administration, probes transit the gastrointestinal tract intact until they reach the microbiome in the large intestine. There, probes are cleaved by GUS and release volatile reporters, which are rapidly exhaled to provide a near real-time breath signal for GUS activity that can be measured via mass spectrometry. In mouse studies, breath signals were produced in naïve mice with GUS-expressing microbiome but absent in microbiome-depleted mice. Repeated probe dosing and breath analysis enabled monitoring of dynamic changes in GUS activities.

Indexed as

Gastrointestinal MicrobiomeGlucuronidaseMicrobiotaAdministration, OralAnimalsBreath TestsHumansMiceGlucuronidase

Identifiers

PMID42600024
PMCPMC13475483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.